Autologous stem cell transplantation in lymphoma

被引：27
作者：
Schmitz, Norbert [1 ]
Buske, Christian [1 ]
Gisselbrecht, Christian [1 ]
机构：
[1] ASKLEPIOS Klin St Georg, Dept Hematol & Stem Cell Transplantat, D-20099 Hamburg, Germany
来源：
SEMINARS IN HEMATOLOGY | 2007年 / 44卷 / 04期
关键词：
D O I：
10.1053/j.seminhematol.2007.08.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
High-dose therapy (HDT) followed by autologous transplantation of hematopoietic stem cells (ASCT) is frequently performed in patients with lymphoma. For many subentities, reliable results from prospective randomized studies are missing. In Hodgkin's disease (HD), HDT/ASCT is a standard indication for patients with chemosensitive first relapse. Patients with indolent or aggressive B-cell lymphoma may benefit from HDT/ASCT if considered as part of first-line therapy or at the time of relapse. However, new randomized studies comparing HDT/ASCT with optimal chemoimmunotherapy are necessary because the introduction of monoclonal antibodies (rituximab) significantly improved the results of conventional chemotherapy. Because data on patients with less frequent entities like mantle cell lymphoma, T-cell lymphoma, Burkitt's lymphoma, or lymphoblastic lymphoma are insufficient, the role of HDT/ASCT needs further study. © 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码：234 / 245
页数：12
相关论文
共 83 条
[1]   Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure:: A case-control study [J].
André, M ;
Henry-Amar, M ;
Pico, JL ;
Brice, P ;
Blaise, D ;
Kuentz, M ;
Coiffier, B ;
Colombat, P ;
Cahn, JY ;
Attal, M ;
Fleury, J ;
Milpied, N ;
Nedellec, G ;
Biron, P ;
Tilly, H ;
Jouet, JP ;
Gisselbrecht, C .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :222-229
[2]   Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma [J].
Apostolidis, J ;
Foran, JM ;
Johnson, PWM ;
Norton, A ;
Amess, J ;
Matthews, J ;
Bradburn, M ;
Lister, TA ;
Rohatiner, AZS .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :216-221
[3]   Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group [J].
Baetz, T ;
Belch, A ;
Couban, S ;
Imrie, K ;
Yau, J ;
Myers, R ;
Ding, K ;
Paul, N ;
Shepherd, L ;
Iglesias, J ;
Meyer, R ;
Crump, M .
ANNALS OF ONCOLOGY, 2003, 14 (12) :1762-1767
[4]   Rituximab combined to ACVBP (R-ACVBP) as a new inductive treatment followed by high-dose consolidative autotransplantation (HDC) for poor risk diffuse large B-cell lymphoma (DLBCL) in first-line.: Preliminary results on 119 patients of a GELA phase II study. [J].
Belhadi, Karim ;
Fitoussi, Olivier ;
Haioun, Corinne ;
Mounier, Nicolas ;
Lederlin, Pierre ;
Coiffier, Bertrand ;
Recher, Christian ;
Casasnovas, Olivier ;
Sebban, Catherine ;
Ferme, Christophe ;
Tilly, Herve ;
Gisselbrecht, Christian .
BLOOD, 2006, 108 (11) :868A-868A
[5]   Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma [J].
Berglund, Å ;
Enblad, G ;
Carlson, K ;
Glimelius, B ;
Hagberg, H .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2000, 65 (01) :17-22
[6]   Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL) [J].
Betticher, D. C. ;
Martinelli, G. ;
Radford, J. A. ;
Kaufmann, M. ;
Dyer, M. J. S. ;
Kaiser, U. ;
Aulitzky, W. E. ;
Beck, J. ;
von Rohr, A. ;
Kovascovics, T. ;
Cogliatti, S. B. ;
Cina, S. ;
Maibach, R. ;
Cerny, T. ;
Linch, D. C. .
ANNALS OF ONCOLOGY, 2006, 17 (10) :1546-1552
[7]  
Brice P, 1996, CANCER-AM CANCER SOC, V78, P1293, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1293::AID-CNCR18>3.0.CO
[8]  
2-W
[9]   High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol [J].
Brice, P ;
Simon, D ;
Bouabdallah, R ;
Bélanger, C ;
Haïoun, C ;
Thieblemont, C ;
Tilly, H ;
Harousseau, JL ;
Doyen, C ;
Martin, C ;
Brousse, N ;
Solal-Céligny, P .
ANNALS OF ONCOLOGY, 2000, 11 (12) :1585-1590
[10]  
Buske C, 2006, HAEMATOLOGICA, V91, P104
123456789